1/1
Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase 3 trials (BRAVE-AA1 and BRAVE-AA2)
media
posted on 2023-02-26, 22:38 authored by Adis journalson behalf of, Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair, Taisuke Ito, Yves Dutronc, Chen-Yen Lin, Guanglei Yu, Chiara Chiasserini, Jill McCollam, Wen-Shuo Wu, Brett KingArticle full text
The above video abstract and plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2023
